{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-045527","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.849901+00:00","generated_at":"2026-05-16T03:27:59.456969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Veru Q1 net loss narrows to $5.3M; cash $33M; Phase 2b obesity trial on track","bullets":["Net loss of $5.3M ($0.26 per share) vs $8.9M ($0.61) in Q1 FY2025.","Cash, cash equivalents and restricted cash increased to $33.0M from $15.8M at Sep 30, 2025.","Operating loss from continuing operations improved to $5.4M from $10.2M.","Phase 2b PLATEAU trial of enobosarm+semaglutide in obesity to start Q1 2026; interim analysis Q1 2027.","R&D spend fell to $1.3M from $5.7M; G&A to $4.1M from $5.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-045527","json":"https://secwatch.observer/filing/0001193125-26-045527.json","markdown":"https://secwatch.observer/filing/0001193125-26-045527.md","text":"https://secwatch.observer/filing/0001193125-26-045527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/0001193125-26-045527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:27:59.456969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}